ACIU - AC Immune SA

-

$undefined

N/A

(N/A)

AC Immune SA NasdaqGM:ACIU AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines, and therapeutic and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. The company's SupraAntigen and Morphomer platforms are designed to generate biologics and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. It develops Crenezumab, a humanized, conformation specific monoclonal antibody used to slow Alzheimer's disease (AD) progression; and Semorinemab, an investigational monoclonal anti Tau antibody that targets the N-terminal portion of the Tau protein and is designed to bind to Tau and slow its spread between neurons for the treatment of AD. The company is also developing ACI-24.060 for the treatment of down syndrome related AD; ACI-7104.056 to treat Parkinson's disease; and ACI-35.030, designs to stimulate a patient's immune system to produce antibodies against pathological phosphorylated Tau. In addition, it develops diagnostic programs consisting of PI-2620, a Tau diagnostic for AD, as well as non-AD Tauopathies; and ACI-12589, a-sync PET tracer that supports the differential diagnosis of multiple system atrophy from other neurodegenerative disease. Further, the company is researching and developing Morphomer Tau aggregation inhibitors to evaluate candidates in AD; Morphomer a-syn to compete with small molecule inhibitors of a-syn aggregation; and NeuroOrphan Tauopathies. Additionally, it generates discovery and preclinical stage molecules targeting range of neurodegenerative diseases, which include diagnostics targeting TDP-43, alpha-synuclein, and NLRP3. The company has license agreements and collaborations with Genentech, Inc.; Janssen Pharmaceuticals, Inc.; Life Molecular Imaging SA; and Eli Lilly and Company. AC Immune SA was incorporated in 2003 and is headquartered in Lausanne, Switzerland.

Location: Building B, Building B, Lausanne, 1015, Switzerland | Website: https://www.acimmune.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

31.26M

Cash

145.6M

Avg Qtr Burn

N/A

Short % of Float

3.59%

Insider Ownership

38.01%

Institutional Own.

26.11%

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
PI-2620 Details
Neurological disorder, Alzheimer's disease

Phase 3

Data readout

JNJ-2056 (prev. ACI-35.030 or JACI-35.054) Details
Neurological disorder, Alzheimer's disease

Phase 2b

Data readout

ACI-7104.056 Details
Parkinson's disease

Phase 2

Data readout

Crenezumab Details
Alzheimer's disease, Neurological disorder

Phase 2

Update

Semorinemab Details
Neurological disorder, Alzheimer's disease

Phase 2

Update

ACI-24.060 (anti-Abeta vaccine) Details
Neurological disorder, Alzheimer's disease, Down Syndrome

Phase 1/2

Data readout

Phase 1

Data readout

Phase 1

Data readout

AC1-3024 Details
Neurological disorder

Failed

Discontinued